Tumor specific MUC1 expression in operable lung cancer correlates with improved survival Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005
The expression of Bcl-xl correlates with improved survival in chemo-naive, surgically resected NSCLC patients Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007
Factors influencing the early cancer relapse in patients with completely resected NSCLC Source: Annual Congress 2008 - Congenital lung lesions and emphysema; lung cancer surgery Year: 2008
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009
Importance of CYFRA-21 in estimation of survival of patients with NSCLC Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Carbohydrate-induced conformational MUC1 tumor-epitope correlates with improved post-surgical survival of non-small cell lung cancer patients with local or distant metastasis Source: Eur Respir J 2006; 28: Suppl. 50, 150s Year: 2006
Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy Source: Eur Respir Rev 2013; 22: 565-576 Year: 2013
Early recurrence in complete resected non-small cell lung cancer patients Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017
Clinical factors of long-term survival in patients with advanced lung cancer Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Prognostic factors affecting survival in advanced non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004
The prognostic impact of stage and performance status on surgically resected non-small cell lung cancer Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
Immunohistochemical study of intratumoral micro vessels in resected non-small cell lung carcinomas, N-status, pTNM-stage and survival period of the patients Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007
Long-term results of surgically treated non-small cell lung cancer patients depending on the protocol of preoperative N-staging Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
The survival in elderly patients after resection of lung cancer Source: Annual Congress 2008 - Congenital lung lesions and emphysema; lung cancer surgery Year: 2008
Correlation between tumour size and survival in surgically treated patients with lung cancer, stage IA or B Source: Eur Respir J 2007; 30: Suppl. 51, 670s Year: 2007
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Evaluation of promoter hypermethylation in tissue and blood of non-small cell lung cancer patients and association with survival. Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019
The predictive value of neuroendocrine markers for response to chemotherapy and survival in patients with non-small cell lung Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006